Vialwirebiotech, curated
November 21, 2026, 5:28 AM
November 17, 2026
- 5:18 AM · Bloomberg — Technology5:18 AMNvidia Forms Export Control Board Committee After Chip Curbs — Bloomberg — Technology
- 5:00 AM · Drug Discovery World5:00 AMFirst-in-class SIK2 inhibitor enters Phase I trial — Drug Discovery World
- 4:00 AM · Drug Discovery World4:00 AMAstraZeneca buys conjugate vaccine developer Omniose — Drug Discovery World
November 16, 2026
- 3:56 PM · STAT News
- 1:54 PM · STAT News
- 11:15 AM · Pharmaceutical Technology11:15 AMRevMed CEO on tackling “complex” launch for wonder pancreatic drug — Pharmaceutical Technology
- 11:00 AM · BioWorld11:00 AMCDC targeting West Nile with development of diagnostics, vaccines — BioWorld
- 11:00 AM · BioWorld11:00 AMJ&J-Ollin, Lilly-Calytrix M&As worth $4.8B combined — BioWorld
- 10:13 AM · Drug Discovery World10:13 AMLarge-scale immune response dataset partnership — Drug Discovery World
- 10:00 AM · FT — Pharmaceuticals10:00 AMSix-year-olds: Novo’s new frontier for weight-loss drugs — FT — Pharmaceuticals
- 8:07 AM · STAT News
- 8:00 AM · BioWorld8:00 AMCDK9/cyclin T1 inhibitors divulged in Czech Academy of Sciences patent — BioWorld
- 8:00 AM · STAT News
- 8:00 AM · BioWorld8:00 AMEMA recommends orphan drug designation for Saniona’s SAN-2668 — BioWorld
- 8:00 AM · BioWorld8:00 AMIdeaya selects candidate for <em>CDKN2A</em>-deficient cancers — BioWorld
- 8:00 AM · BioWorld8:00 AMShenzhen Salubris patents new apelin receptor agonists — BioWorld
- 8:00 AM · BioWorld8:00 AMArexera’s ATL-101 for Huntington’s disease cleared for clinic — BioWorld
- 8:00 AM · BioWorld8:00 AMHangzhou Baicreat Pharma-Tech reports new NLRP3 inflammasome inhibitors — BioWorld
- 8:00 AM · BioWorld8:00 AMCARB-X supports UNSW Sydney’s synthetic darobactin analogues — BioWorld
- 7:44 AM · BioPharma Dive7:44 AMLilly adds to buyout streak with $1.5B purchase of startup Calytrix — BioPharma Dive
- 6:32 AM · Bloomberg — Technology6:32 AMFlagship’s Afeyan Sees UK Bet Creating Next Moderna — Bloomberg — Technology
- 5:00 AM · STAT News
- 5:00 AM · BioPharma Dive5:00 AMBig-name investors pour $100M into DNA therapeutics developer Seawolf — BioPharma Dive
- 4:37 AM · Pharmaceutical Technology4:37 AMAstraZeneca secures FDA approval for Imfinzi combo in MIBC — Pharmaceutical Technology
- 4:30 AM · STAT News4:30 AMBeOne, Hengrui top list of China’s most powerful drugmakers — STAT News
November 15, 2026
- 6:54 PM · FT — Pharmaceuticals6:54 PMJohnson & Johnson looking to buy eye disease biotech for up to $3.4bn — FT — Pharmaceuticals